Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal
carcinoma patients

J 2013

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients

HALÁMKOVÁ, Jana, Igor KISS, Zdeněk PAVLOVSKÝ, Jiří TOMÁŠEK, Jiří JARKOVSKÝ et. al.

Základní údaje

Originální název

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients

Autoři

HALÁMKOVÁ, Jana (203 Česká republika, garant, domácí), Igor KISS (203 Česká republika, domácí), Zdeněk PAVLOVSKÝ (203 Česká republika, domácí), Jiří TOMÁŠEK (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Zbyněk ČECH (203 Česká republika, domácí), D. BEDNAROVA (203 Česká republika), Štěpán TUČEK (203 Česká republika, domácí), L. HANAKOVA (203 Česká republika), Mojmír MOULIS (203 Česká republika, domácí), Jiřina ZAVŘELOVÁ (203 Česká republika), M. MAN (203 Česká republika), Petr BENDA (203 Česká republika, domácí), Oldřich ROBEK (203 Česká republika, domácí), Zdeněk KALA (203 Česká republika, domácí) a Miroslav PENKA (203 Česká republika, domácí)

Vydání

Neoplasma, BRATISLAVA, SLOVAK ACAD SCIENCES, 2013, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.642

Kód RIV

RIV/00216224:14110/13:00071537

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2013_020

UT WoS

000320086800005

Klíčová slova anglicky

plasminogen activator system; gastrointestinal cancer; plasminogen activator inhibitor 1; -675 4G/5G gene polymorphism

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 2. 2014 16:11, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Plasminogen activator ihnibitor (PAI 1) belongs to the plasminogen activator system, which is part of the metastatic cascade and significantly contributes to invasive growth and angiogenesis of malignant tumors. Its plasma level is normally low but 4G/4G homozygotes have higher concentrations of PAI 1. This genotype may be associated with worse prognosis and proximal location of colorectal cancer than 5G/5G homozygotes. In our prospective evaluation we examined plasma level PAI 1 (using photometric microplate method ELISA) pre-surgery and, subsequently, 6-8 weeks later, from 80 patients. For the PAI 1 rs1799889 -675 4G/5G polymorphism test the PCR amplification was used. Analysis of collected data was confirmed that significantly higher plasma levels of PAI 1 were found in patients before starting therapy, which decreased (p=0.004) after initiation of treatment. Patients with higher plasma level PAI 1 before (p=0.013) and after therapy (p=0.004) had significantly shorter survival. We found no relationship between polymorphisms of PAI 1 (-675 4G/5G) in relation to stage, survival or tumor location. PAI 1 is useful as a negative marker of prognosis and could be advantageous when planning adjuvant treatment of patients with colorectal carcinoma. Although opinions on the importance of polymorphisms of PAI 1 in relation to the prognosis are not uniform, it does seem that their role in the prognosis of patients with colorectal cancer is not essential.

Citovat

HALÁMKOVÁ, Jana, Igor KISS, Zdeněk PAVLOVSKÝ, Jiří TOMÁŠEK, Jiří JARKOVSKÝ, Zbyněk ČECH, D. BEDNAROVA, Štěpán TUČEK, L. HANAKOVA, Mojmír MOULIS, Jiřina ZAVŘELOVÁ, M. MAN, Petr BENDA, Oldřich ROBEK, Zdeněk KALA a Miroslav PENKA. Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. Neoplasma. BRATISLAVA: SLOVAK ACAD SCIENCES, 2013, roč. 60, č. 2, s. 151-159. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2013_020.

@article{1161702,
   author = {Halámková, Jana and Kiss, Igor and Pavlovský, Zdeněk and Tomášek, Jiří and Jarkovský, Jiří and Čech, Zbyněk and Bednarova, D. and Tuček, Štěpán and Hanakova, L. and Moulis, Mojmír and Zavřelová, Jiřina and Man, M. and Benda, Petr and Robek, Oldřich and Kala, Zdeněk and Penka, Miroslav},
   article_location = {BRATISLAVA},
   article_number = {2},
   doi = {http://dx.doi.org/10.4149/neo_2013_020},
   keywords = {plasminogen activator system; gastrointestinal cancer; plasminogen activator inhibitor 1; -675 4G/5G gene polymorphism},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients},
   volume = {60},
   year = {2013}
}

TY  - JOUR
ID  - 1161702
AU  - Halámková, Jana - Kiss, Igor - Pavlovský, Zdeněk - Tomášek, Jiří - Jarkovský, Jiří - Čech, Zbyněk - Bednarova, D. - Tuček, Štěpán - Hanakova, L. - Moulis, Mojmír - Zavřelová, Jiřina - Man, M. - Benda, Petr - Robek, Oldřich - Kala, Zdeněk - Penka, Miroslav
PY  - 2013
TI  - Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients
JF  - Neoplasma
VL  - 60
IS  - 2
SP  - 151-159
EP  - 151-159
PB  - SLOVAK ACAD SCIENCES
SN  - 00282685
KW  - plasminogen activator system
KW  - gastrointestinal cancer
KW  - plasminogen activator inhibitor 1
KW  - -675 4G/5G gene polymorphism
N2  - Plasminogen activator ihnibitor (PAI 1) belongs to the plasminogen activator system, which is part of the metastatic cascade and significantly contributes to invasive growth and angiogenesis of malignant tumors. Its plasma level is normally low but 4G/4G homozygotes have higher concentrations of PAI 1. This genotype may be associated with worse prognosis and proximal location of colorectal cancer than 5G/5G homozygotes. In our prospective evaluation we examined plasma level PAI 1 (using photometric microplate method ELISA) pre-surgery and, subsequently, 6-8 weeks later, from 80 patients. For the PAI 1 rs1799889 -675 4G/5G polymorphism test the PCR amplification was used. Analysis of collected data was confirmed that significantly higher plasma levels of PAI 1 were found in patients before starting therapy, which decreased (p=0.004) after initiation of treatment. Patients with higher plasma level PAI 1 before (p=0.013) and after therapy (p=0.004) had significantly shorter survival. We found no relationship between polymorphisms of PAI 1 (-675 4G/5G) in relation to stage, survival or tumor location. PAI 1 is useful as a negative marker of prognosis and could be advantageous when planning adjuvant treatment of patients with colorectal carcinoma. Although opinions on the importance of polymorphisms of PAI 1 in relation to the prognosis are not uniform, it does seem that their role in the prognosis of patients with colorectal cancer is not essential.
ER  -

HALÁMKOVÁ, Jana, Igor KISS, Zdeněk PAVLOVSKÝ, Jiří TOMÁŠEK, Jiří JARKOVSKÝ, Zbyněk ČECH, D. BEDNAROVA, Štěpán TUČEK, L. HANAKOVA, Mojmír MOULIS, Jiřina ZAVŘELOVÁ, M. MAN, Petr BENDA, Oldřich ROBEK, Zdeněk KALA a Miroslav PENKA. Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. \textit{Neoplasma}. BRATISLAVA: SLOVAK ACAD SCIENCES, 2013, roč.~60, č.~2, s.~151-159. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2013\_{}020.

Podrobný výpis o publikaci